Pan, Pei-Yin
Bölte, Sven
Funding for this research was provided by:
the Swedish Research Council
Vinnova
Formas
FORTE
the Swedish Brain foundation
Stockholm Brain Institute
Autism and Asperger Association Stockholm
Queen Silvia Jubilee Fund
Solstickan Foundation
PRIMA Child and Adult Psychiatry
the Pediatric Research Foundation at Astrid Lindgren Children’s Hospital
Sällskapet Barnavård
the Swedish Foundation for Strategic Research
Jerring Foundation
the Swedish Order of Freemasons
Kempe- Carlgrenska Foundation
Sunnderdahls Handikappsfond
The Jeansson Foundation
EU-AIMS
the Innovative Medicines Initiative Joint Undertaking (no. 115300)
the European Union’s Seventh Framework Programme (grant FP7/2007-2013)
the European Federation of Pharmaceutical Industries and Associations companies’ in-kind contributions
Autism Speaks
EU AIMS-2-TRIALS
Karolinska Institute
Article History
Received: 8 July 2020
Accepted: 27 November 2020
First Online: 28 December 2020
Competing interests
: The authors declare no competing interests. S.B. discloses that he has in the last 5 years acted as an author, consultant or lecturer for Shire, Medice, Roche, and Lilly. He receives royalties for text books and diagnostic tools from Hogrefe, Kohlhammer, and UTB.